Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Codexis Inc (CDXS)

Codexis Inc (CDXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 749,330
  • Shares Outstanding, K 58,359
  • Annual Sales, $ 60,590 K
  • Annual Income, $ -10,880 K
  • 60-Month Beta -0.05
  • Price/Sales 12.28
  • Price/Cash Flow N/A
  • Price/Book 7.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.12
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -125.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.68 +1.26%
on 08/22/19
18.87 -31.96%
on 07/31/19
-5.66 (-30.59%)
since 07/23/19
3-Month
12.68 +1.26%
on 08/22/19
19.71 -34.86%
on 05/28/19
-5.90 (-31.48%)
since 05/23/19
52-Week
12.68 +1.26%
on 08/22/19
23.05 -44.30%
on 12/03/18
-3.01 (-18.99%)
since 08/23/18

Most Recent Stories

More News
Codexis Reports Second Quarter 2019 Financial Results

Product revenue up 68%; R&D revenue spread over wider base of customers and markets

CDXS : 12.84 (+0.71%)
Codexis (CDXS) Reports Q2 Loss, Lags Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of -100.00% and -17.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

CDXS : 12.84 (+0.71%)
Codexis: 2Q Earnings Snapshot

REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Tuesday reported a loss of $6.5 million in its second quarter.

CDXS : 12.84 (+0.71%)
Codexis Names Ross Taylor Senior Vice President and Chief Financial Officer

Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces the appointment of Ross Taylor as Senior Vice President and Chief Financial Officer effective August 19, 2019. Mr. Taylor...

CDXS : 12.84 (+0.71%)
ABAX : 83.00 (-0.11%)
Codexis to Hold Second Quarter 2019 Conference Call on August 6

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2019 financial results after market close on Tuesday, August 6, 2019. Codexis management...

CDXS : 12.84 (+0.71%)
Casdin Capital Invests $50 Million in Codexis to Accelerate Strategic Growth Initiatives

Codexis, Inc. (Nasdaq: CDXS), a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has...

CDXS : 12.84 (+0.71%)
Codexis Announces CodeEvolver(R) Technology Transfer and License Agreement with Global Pharmaceutical Leader

Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces the signing of a CodeEvolver platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive...

CDXS : 12.84 (+0.71%)
NVS : 88.44 (-0.63%)
Codexis to Participate at Three Investment Conferences in May

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in three upcoming investment conferences:

CDXS : 12.84 (+0.71%)
Codexis (CDXS) Reports Q1 Loss, Tops Revenue Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 16.67% and 5.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CDXS : 12.84 (+0.71%)
Codexis: 1Q Earnings Snapshot

REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Monday reported a loss of $5.1 million in its first quarter.

CDXS : 12.84 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CDXS with:

Business Summary

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and...

See More

Key Turning Points

2nd Resistance Point 13.75
1st Resistance Point 13.30
Last Price 12.84
1st Support Level 12.59
2nd Support Level 12.33

See More

52-Week High 23.05
Fibonacci 61.8% 19.09
Fibonacci 50% 17.86
Fibonacci 38.2% 16.64
Last Price 12.84
52-Week Low 12.68

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar